Impact of UDP-gluconoryltransferase 2B17 genotype on vorinostat metabolism and clinical outcomes in Asian women with breast cancer

Objectives Vorinostat, a histone deacetylase inhibitor being actively evaluated in solid tumors, is metabolized by UGT2B17. UGT2B17 null genotype (UGT2B17*2) has been shown in vitro to reduce UGT2B17 activity. This variant is common in Asians but rare in Caucasians, and we studied its impact on vorinostat pharmacokinetics and pharmacodynamics in a clinical study in Asian patients with metastatic breast cancer. Methods Eligible patients received 400 mg of vorinostat monotherapy daily in a lead-in phase I followed by a phase II study. Patients were genotyped for UGT2B17*2, which was correlated with vorinostat pharmacokinetics and clinical outcomes. Results Twenty- six patients were treated with no complete response, one partial response, six stable disease lasting for 12 weeks or more, and 19 progressive disease. Sixteen patients (62%) were UGT2B17*2 homozygotes and had significantly lower mean area under the curve ratio of vorinostat-O-glucuronide/vorinostat (1.84 vs. 2.51 on day 1, P = 0.02; 1.63 vs. 2.38 on day 15, P = 0.028), and trended toward having higher vorinostat area under the curve (399.02 vs. 318.40, P = 0.188), more serious adverse events (31 vs. 0%, P = 0.121), higher clinical benefit rate (40 vs. 10%, P = 0.179), and longer median progression-free survival (3.0 vs. 1.5 months, P = 0.087) than patients with at least one wild-type allele. Conclusion UGT2B17*2 genotype reduces vorinostat glucuronidation and may increase vorinostat efficacy and toxicity. These observations are important in the development of vorinostat, and may have clinical implications on other cancer and noncancer drugs that are UGT2B17 substrates such as exemestane and ibuprofen. Pharmacogenetics and Genomics 21:760-768 (C) 2011 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.